首页> The Prostate> Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.

Bayesian predictive model to assess BRCA2 mutational status according to clinical history: Early onset, metastatic phenotype or family history of breast/ovary cancer.

导出 LinkOut

翻译打印收藏纠错

第一作者： Priscilla,Leon

第一单位： Department of Urology, Clinique Pasteur, Royan, France.;GRC n°5 Predictive Onco-Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.

作者： Priscilla,Leon ^[1] ; Geraldine,Cancel-Tassin ^[2] ; Violaine,Bourdon ^[3] ; Bruno,Buecher ^[4] ; Stephane,Oudard ^[5] ; Laurent,Brureau ^[6] ; Lionel,Jouffe ^[7] ; Pascal,Blanchet ^[6] ; Dominique,Stoppa-Lyonnet ^[4] ; Florence,Coulet ^[8] ; Hagay,Sobol ^[3] ; Olivier,Cussenot ^[2]

作者单位： Department of Urology, Clinique Pasteur, Royan, France.;GRC n°5 Predictive Onco-Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France. ^[1] GRC n°5 Predictive Onco-Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.;CeRePP, Paris, France. ^[2] Department of Prevention and Screening Genetic Oncology, Institut Paoli-Calmettes, Marseille, France. ^[3] Department of Genetics, Institut Curie, Paris, France. ^[4] Department of Oncology Unit, Georges Pompidou European Hospital, APHP, Paris, France. ^[5] Department of Urology, Pointe-à-Pitre/Abymes University Hospital, Pointe a Pitre, Guadeloupe.;UMR_S 1085, EHESP, Research Institute in Health, Environment and Work (IRSET), Inserm, Pointe-à-Pitre, Guadeloupe. ^[6] Bayesia SAS, Changé, France. ^[7] Department of Genetics, Oncogenetics Consulting, Oncogenetics Functional Unit, Groupe Hospitalier Pitié-Salpêtrière APHP, Paris, France. ^[8]

关键词 BRCA2 DNA damage and repair mutation prostate cancer survival